GlassScriptPhysician profile
Nishith M Gami
NPI 1295786440
$3,846.68
in general payments reported to CMS, 2019-2025
26 companies · $646 in 2025
The $646 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $563 · 2020: $519 · 2021: $497 · 2022: $558 · 2023: $431 · 2024: $633 · 2025: $646.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,710.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,709.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,311.79 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $521.57 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Astrazeneca Pharmaceuticals LP | $450.51 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Astellas Pharma US INC | $202.11 | 2019-2023 | Myrbetriq, Veozah |
| Amarin Pharma, INC. | $196.25 | 2020-2022 | |
| Amgen INC. | $180.05 | 2020-2025 | Otezla, Repatha, Otezla |
| Allergan, INC. | $168.00 | 2019 | |
| Pfizer INC. | $162.34 | 2023-2025 | |
| Exact Sciences Corporation | $134.55 | 2024-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $109.26 | 2024-2025 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $94.42 | 2020-2021 | |
| Endo Pharmaceuticals INC. | $39.89 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.95 | 2019 | |
| Merck Sharp & Dohme LLC | $31.47 | 2025 | Lagevrio |
| E.R. Squibb & Sons, L.L.C. | $31.47 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $27.31 | 2020 | |
| Ironwood Pharmaceuticals, INC | $24.78 | 2020 | |
| Alnylam Pharmaceuticals INC. | $16.03 | 2025 | Onpattro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.29 | 2024 | |
| Xeris Pharmaceuticals, INC. | $14.65 | 2024 | Gvoke Hypopen |
| Vifor Pharma, INC. | $14.57 | 2023 | Veltassa |
| Nestle Healthcare Nutrition INC. | $13.32 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $12.97 | 2019 | |
| Qiagen, LLC | $12.66 | 2021 | |
| Dexcom, INC. | $11.82 | 2021 | |
| Sumitomo Pharma America, INC. | $10.65 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nishith Gami listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.